Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Shares, par value CHF 0.08 per share
-
Shares outstanding
-
124,261,423
-
Total 13F shares
-
82,855,836
-
Share change
-
+14,892,279
-
Total reported value
-
$292,809,813
-
Put/Call ratio
-
0%
-
Price per share
-
$3.53
-
Number of holders
-
113
-
Value change
-
+$51,266,770
-
Number of buys
-
67
-
Number of sells
-
38
Institutional Holders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) as of Q4 2025
As of 31 Dec 2025,
ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) was held by
113 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
82,855,836 shares.
The largest 10 holders included
Redmile Group, LLC, TCG Crossover Management, LLC, Prosight Management, LP, ORBIMED ADVISORS LLC, Nantahala Capital Management, LLC, BlackRock, Inc., Point72 Asset Management, L.P., MORGAN STANLEY, EVENTIDE ASSET MANAGEMENT, LLC, and GOLDMAN SACHS GROUP INC.
This page lists
113
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.